European Journal of Clinical Microbiology & Infectious Diseases

Papers
(The H4-Index of European Journal of Clinical Microbiology & Infectious Diseases is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation86
Evaluation of two rapid phenotypical tests—Alifax rapid AST colistin test and Rapid Polymyxin NP test—for detection of colistin resistance in Enterobacterales61
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area57
Clinical characteristics and risk factor analysis of Pneumocystis jirovecii pneumonia in patients with CKD: a machine learning–based approach54
Melaleuca alternifolia essential oil soap: a potential alternative for hand hygiene49
Retraction Note: A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort48
Brief report: community-acquired Friedlander’s pneumonia and pulmonary metastatic Klebsiella pneumoniae infection caused by hypervirulent ST23 in the Netherlands47
Laboratory and clinical predictors of focal involvement and bacteremia in brucellosis45
Genome-wide association study of SARS-CoV-2 infection in Chinese population43
Reduction of antibiotic use and multi-drug resistance bacteria infection in neonates after improvement of antibiotics use strategy in a level 4 neonatal intensive care unit in southern China39
Author’s reply38
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study37
Ocular thelaziosis: an emerging human parasitosis in Europe37
In vivo efficacy of combination therapy with albendazole and atovaquone against primary hydatid cysts in mice34
Follow-up blood cultures in Staphylococcus aureus bacteremia: a probability-based optimization33
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019–2020)33
Real-time recombinase-aided amplification assay for rapid amplification of the IS1081 gene of Mycobacterium tuberculosis31
Seasonal variations in blood culture numbers and time to positivity and potential impact of reducing incubation periods31
The ID NOW COVID-19, a high-speed high-performance assay30
Investigation of the presence of Capnophilic bacteria in routine urine cultures30
Persistent headaches one year after bacterial meningitis: prevalence, determinants and impact on quality of life25
Antimicrobial use, healthcare-associated infections, and bacterial resistance in general hospitals in China: the first national pilot point prevalence survey report25
Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae24
Real-world effectiveness of casirivimab plus indevimab in a dedicated ambulatory unit created for patients with early COVID-19 during a massive delta variant wave23
0.092095136642456